Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3919797 | 1.00 | CCR8 (1.00) | CCR8KCNH2 | |
| SCHEMBL3930474 | 0.87 | CCR8 (1.00) | CCR8KCNH2 | |
| SCHEMBL3930467 | 0.87 | CCR8 (1.00) | CCR8KCNH2 | |
| SCHEMBL4718802 | 0.85 | CCR8 (0.74) | CCR8KCNH2 | |
| SCHEMBL3923708 | 0.81 | CCR8 (0.69) | CCR8KCNH2 | |
| SCHEMBL3923700 | 0.81 | CCR8 (0.69) | CCR8KCNH2 | |
| SCHEMBL13923506 | 0.79 | CCR8 (0.67) | CCR8KCNH2 | |
| SCHEMBL3930004 | 0.79 | CCR8 (0.65) | CCR8KCNH2 | |
| SCHEMBL3929996 | 0.79 | CCR8 (0.65) | CCR8KCNH2 | |
| SCHEMBL3933997 | 0.78 | CCR8 (0.63) | CCR8KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567520-B1 | QUINOLINES AND NITROGENATED DERIVATIVES THEREOF AND THEIR USE AS ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2008-10-15 | — | — | EP | claimed |
| EP-1567520-A4 | QUINOLINES AND NITROGENATED DERIVATIVES THEREOF AND THEIR USE AS ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2006-08-02 | — | — | EP | claimed |
| JP-2006515862-A | — | — | 2006-06-08 | — | — | JP | claimed |
| US-20060116512-A1 | Quinolines and nitrogenated derivatives thereof and their use as antibacterial agents | GLAXO GROUP LIMITED (GB) | 2006-06-01 | — | — | US | claimed |
| EP-1567520-A2 | QUINOLINES AND NITROGENATED DERIVATIVES THEREOF AND THEIR USE AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2005-08-31 | — | — | EP | claimed |
| WO-2004050036-A2 | QUINOLINES AND NITROGENATED DERIVATIVES THEREOF AND THEIR USE AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2004-06-17 | — | — | WO | claimed |
| US-7491714-B2 | Quinolines and nitrogenated derivatives thereof and their use as antibacterial agents | GLAXO GROUP LIMITED (GB) | 2009-02-17 | — | — | US | disclosed |
| EP-1567520-B1 | QUINOLINES AND NITROGENATED DERIVATIVES THEREOF AND THEIR USE AS ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2008-10-15 | — | — | EP | disclosed |
| EP-1567520-A4 | QUINOLINES AND NITROGENATED DERIVATIVES THEREOF AND THEIR USE AS ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2006-08-02 | — | — | EP | disclosed |
| US-20060116512-A1 | Quinolines and nitrogenated derivatives thereof and their use as antibacterial agents | GLAXO GROUP LIMITED (GB) | 2006-06-01 | — | — | US | disclosed |
| EP-1567520-A2 | QUINOLINES AND NITROGENATED DERIVATIVES THEREOF AND THEIR USE AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004050036-A2 | QUINOLINES AND NITROGENATED DERIVATIVES THEREOF AND THEIR USE AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116512-A1 | Quinolines and nitrogenated derivatives thereof and their use as antibacterial agents | NQO2, NQO1, NPM1 | CCR8 4506/4885KCNH2 2541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.